400 filings
Page 13 of 20
6-K
qhuo rdnt83vfi4
22 Nov 17
Acasti Pharma Clarifies Term of Proposed Strategic Partnership with Leading China Pharmaceutical Company
12:00am
6-K
69i4nvir0 5b3i
20 Nov 17
Acasti Pharma Announces Development and Commercialization Discussions Progressing with a Leading China Pharmaceutical Partner
12:00am
F-1/A
msyf509c nidpn
16 Nov 17
Registration statement (foreign) (amended)
12:00am
CORRESP
hc15cho0h4mr165u
16 Nov 17
Correspondence with SEC
12:00am
6-K
3sm5wi62alneq
14 Nov 17
Current report (foreign)
12:00am
6-K
vbi4vg 965
13 Nov 17
Acasti Pharma Reports Second Quarter FY 2018 Financial Results
12:00am
6-K
fkpz7yicrgmrg7tsgwp
7 Nov 17
Acasti Pharma Announces Dariush Mozaffarian, M.D., Dr.P.H. Principal Investigator for CaPre Phase 3 Development Program
12:00am
UPLOAD
aprlfd32luuofk9l
11 Oct 17
Letter from SEC
12:00am
6-K
lavpnjhjip 4g
5 Oct 17
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
12:00am
F-1
wh5ll
29 Sep 17
Registration statement (foreign)
12:00am
6-K
io4e2kb5z1ascdx
1 Sep 17
Current report (foreign)
12:00am
6-K
yp670ozavz7r3 jn3g
25 Aug 17
Form 51-102F3 Material Change Report
12:00am
6-K
isli0xz1egdvdka dvc
17 Aug 17
Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM
12:00am
6-K
b078t e78s
15 Aug 17
Current report (foreign)
12:00am
6-K
mo1g jrpso37
14 Aug 17
Acasti Pharma Reports First Quarter FY 2018 Financial Results
12:00am
6-K
9oh4f i430h
28 Jul 17
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures
12:00am
6-K
bbggwtnmk5hi
17 Jul 17
Notice of Annual and Special Meeting of Shareholders
12:00am
6-K
z1sbaq8cn
16 Jun 17
Acasti Pharma Inc. 6-K
12:00am
6-K
wj5appr qki8
14 Jun 17
Acasti Pharma Inc. 6-K
12:00am